| Literature DB >> 31825987 |
Larissa Martins Melo1, Jaqueline Poleto Bragato1, Gabriela Lovizutto Venturin1, Gabriela Torres Rebech1, Sidnei Ferro Costa1, Leandro Encarnação Garcia2, Flávia Lombardi Lopes2, Flávia de Rezende Eugênio1, Paulo Sérgio Patto Dos Santos1, Valéria Marçal Felix de Lima1.
Abstract
Visceral Leishmaniasis is a chronic zoonosis and, if left untreated, can be fatal. Infected dogs have decreased cellular immunity (Th1) and develop a potent humoral response (Th2), which is not effective for elimination of the protozoan. Immune response can be modulated by microRNAs (miRNAs), however, characterization of miRNAs and their possible regulatory role in the spleen of infected dogs have not been done. We evaluated miRNA expression in splenic leukocytes (SL) from dogs naturally infected with Leishmania infantum and developing leishmaniasis (CanL; n = 8) compared to healthy dogs (n = 4). Microarray analysis showed increased expression of miR 21, miR 148a, miR 7 and miR 615, and downregulation of miR 150, miR 125a and miR 125b. Real-time PCR validated the differential expression of miR 21, miR 148a and miR 615. Further, decrease of miR 21 in SL, by means of transfection with a miR 21 inhibitor, increased the IL-12 cytokine and the T-bet/GATA-3 ratio, and decreased parasite load on SL of dogs with CanL. Taken together, these findings suggest that L. infantum infection alters splenic expression of miRNAs and that miR 21 interferes in the cellular immune response of L. infantum-infected dogs, placing this miRNA as a possible therapeutic target in CanL.Entities:
Year: 2019 PMID: 31825987 PMCID: PMC6905561 DOI: 10.1371/journal.pone.0226192
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Differentially expressed miRNAs in SL of dogs with CanL.
(A) Representation of the 7 miRNAs differentially expressed in SL of dogs with CanL in comparison to healthy dogs. Heat map lines represent individual miRNAs and the columns represent individual samples (eight dogs with CanL and four control dogs). Color scale represents normalized expression levels of miRNAs in the two conditions on the log2 scale; red denotes up-regulation and green denotes down-regulation. (B) Volcano plot. On the left are miRNAs with negative expression (green) and miRNAs with positive expression (red). Analysis of variances (ANOVA) was used between groups, and significance was considered at Fold Change greater than +/-2 and p<0.05. (C) Expression of miRNAs in the infected and control groups was quantified by real-time PCR in SL. Data represent mean of miRNA expression + standard error of the mean. Asterisks represent significance (p<0.05) by Mann-Whitney test.
Thirty major canonical pathways predicted for differentially expressed miRNAs in CanL.
| Ingenuity Canonical Pathways | P value | Target miRNAs | Target genes |
|---|---|---|---|
| Neuregulin Signaling | 0.0001 | miR 148a | CDK5R1, ERBB3, ERRFI1, MRAS, NRAS, PRKCZ, PTEN, SOS1, SOS2, TGFA |
| miR 21 | PIK3R1, PTEN | ||
| miR 615 | PRKCG | ||
| STAT3 Pathway | 0.0010 | miR 148a | FLT1, MAP3K9, MRAS, NRAS, TGFA |
| miR 21 | BMPR2, CDC25A, CDKN1A, SOCS5, TGFBR2 | ||
| miR 615 | MAPK13 | ||
| PTEN Signaling | 0.0010 | miR 148a | FLT1, MRAS, NRAS, PRKCZ, PTEN, SOS1, SOS2 |
| miR 21 | BMPR2, CDKN1A, FASLG, PIK3R1, PTEN, TGFBR2 | ||
| HER-2 Signaling in Breast Cancer | 0.0015 | miR 148a | ERBB3, MRAS, NRAS, PRKCZ, SOS1, SOS2 |
| miR 21 | CDK6, CDKN1A, PIK3R1 | ||
| miR 615 | PRKCG | ||
| Myc Mediated Apoptosis Signaling | 0.0015 | miR 148a | MRAS, NRAS, PRKCZ, SOS1, SOS2 |
| miR 21 | APAF1, FAS, FASLG, PIK3R1 | ||
| Glioma Signaling | 0.0018 | miR 148a | MRAS, NRAS, PRKCZ, PTEN, SOS1, SOS2, TGFA |
| miR 21 | CDK6, CDKN1A, PIK3R1, PTEN | ||
| miR 615 | PRKCG | ||
| Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells | 0.0019 | miR 148a | HLA-A, HLA-B, HLA-C |
| miR 21 | APAF1, FAS, FASLG | ||
| Neurotrophin/TRK Signaling | 0.0019 | miR 148a | MRAS, NRAS, SOS1, SOS2 |
| miR 21 | NTF3, PIK3R1, SPRY1, SPRY2 | ||
| miR 615 | NTF4 | ||
| ErbB Signaling | 0.0019 | miR 148a | ERBB3, MRAS, NRAS, PRKCZ, SOS1, SOS2, TGFA |
| miR 21 | PIK3R1, MAPK13 | ||
| miR 615 | PRKCG | ||
| Cholecystokinin/Gastrin-mediated Signaling | 0.0021 | miR 148a | CCKBR, FLT1, MRAS, NRAS, PRKCZ, ROCK1, SOS1, SOS2 |
| miR 21 | ACTA2, EIF1AX, PIK3R1, TNF | ||
| miR 615 | MEF2A, PRKCG | ||
| Type I Diabetes Mellitus Signaling | 0.0026 | miR 148a | HLA-A, HLA-B, HLA-C |
| miR 21 | APAF1, FAS, FASLG, IL12A, SOCS5, TNF | ||
| miR 615 | MAPK13 | ||
| TGF-β Signaling | 0.0032 | miR 148a | INHBB, MRAS, NRAS, SOS1, SOS2 |
| miR 21 | BMPR2, SMAD7, TGFBR2 | ||
| miR 615 | MAPK13 | ||
| VEGF Family Ligand-Receptor Interactions | 0.0032 | miR 148a | FLT1, MRAS, NRAS, NRP1, PRKCZ, SOS1, SOS2 |
| miR 21 | PIK3R1 | ||
| miR 615 | PRKCG | ||
| Molecular Mechanisms of Cancer | 0.0038 | miR 148a | CDK19, MRAS, NRAS, PRKCZ, SOS1, SOS2 |
| miR 21 | APAF1, BMPR2, CDC25A, CDK6, CDKN1A, FAS, FASLG, PIK3R1, SMAD7, TGFBR2 | ||
| miR 615 | MAPK13, MAX, PRKCG, RALBP1 | ||
| Th2 Pathway | 0.0056 | miR 148a | BHLHE41, HLA-A, HLA-B, HLA-DQB2, MAF, S1PR1 |
| miR 21 | BMPR2, IL12A, JAG1, PIK3R1, TGFBR2 | ||
| VEGF Signaling | 0.0071 | miR 148a | FLT1, MRAS, NRAS, ROCK1, SOS1, SOS2 |
| miR 21 | ACTA2, EIF1AX, PIK3R1 | ||
| Th1 and Th2 Activation Pathway | 0.0071 | miR 148a | BHLHE41, HLA-A, HLA-B, HLA-DQB2, MAF, S1PR1 |
| miR 21 | BMPR2, IL12A, IL6R, JAG1, PIK3R1, TGFBR2 | ||
| Graft-versus-Host Disease Signaling | 0.0071 | miR 148a | HLA-A, HLA-B, HLA-C |
| miR 21 | FAS, FASLG, TNF | ||
| p53 Signaling | 0.0071 | miR 148a | GADD45A, JMY, MDM4, PTEN |
| miR 21 | APAF1, CDKN1A, FAS, PIK3R1, PTEN, SERPINB5 | ||
| Prolactin Signaling | 0.0071 | miR 148a | MRAS, NRAS, PRKCZ, SOS1, SOS2 |
| miR 21 | PIK3R1, SOCS5 | ||
| miR 615 | PRKCG | ||
| Crosstalk between Dendritic Cells and Natural Killer Cells | 0.0071 | miR 148a | HLA-A, HLA-B, HLA-C |
| miR 21 | ACTA2, FAS, FASLG, IL12A, TNF | ||
| JAK/Stat Signaling | 0.0071 | miR 148a | CCKBR, MRAS, NRAS, SOS1, SOS2 |
| miR 21 | CDKN1A, PIK3R1, SOCS5 | ||
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 0.0077 | miR 148a | GADD45A, MDM4, PRKCZ, SKP1 |
| miR 21 | CDKN1A, SKP2 | ||
| Virus Entry via Endocytic Pathways | 0.0085 | miR 148a | HLA-A, HLA-B, HLA-C, MRAS, NRAS, PRKCZ |
| miR 21 | ACTA2, PIK3R1 | ||
| miR 615 | PRKCG | ||
| HGF Signaling | 0.0100 | miR 148a | MAP3K9, MRAS, NRAS, PRKCZ, SOS1, SOS2 |
| miR 21 | CDKN1A, PIK3R1 | ||
| miR 615 | PRKCG | ||
| p38 MAPK Signaling | 0.0102 | miR 148a | RPS6KA5 |
| miR 21 | FAS, FASLG, TGFBR2, TNF | ||
| miR 615 | HSPB7, MAPK13, MAX, MEF2A | ||
| ErbB2-ErbB3 Signaling | 0.0104 | miR 148a | ERBB3, MRAS, NRAS, PTEN, SOS1, SOS2 |
| miR 21 | PIK3R1, PTEN | ||
| Antigen Presentation Pathway | 0.0112 | miR148a | HLA-A, HLA-B, HLA-C, HLA-DQB2, PDIA3 |
| Fc Epsilon RI Signaling | 0.0112 | miR 148a | MRAS, NRAS, PRKCZ, SOS1, SOS2 |
| miR 21 | PIK3R1, TNF | ||
| miR 615 | MAPK13, PRKCG | ||
| NGF Signaling | 0.0112 | miR 148a | MAP3K9, MRAS, NRAS, PRKCZ, ROCK1, RPS6KA5, SOS1, SOS2 |
| miR 21 | PIK3R1 |
To understand the functional networks of the target genes, Gene Ontology (GO terms) were analyzed. Analysis showed that these target genes were involved in a large number of biological processes where from a total of 1,101 entries, 30 are presented in S8A Table; for cellular component, of a total of 74 entries, 30 are presented in S8B Table; and for molecular function, a total of 151 entries were found, and 30 are presented in S8C Table.
Fig 2IL-12 production.
IL-12 production was quantified in supernatants from SL cultures of dogs transfected with negative control (scrambled), miR 21 mimic, miR 21 inhibitor, all in the presence of Hiperfect (miScript miRNA Mimic and Inhibitor Qiagen, USA), following 67h in culture. SL from dogs naturally infected by L. infantum. Data represent the mean values of IL-12 + SE. Asterisks represent significance (p<0.05) by Friedman Test with multiple comparison.
Fig 3Th1 and Th2 profile.
Th1 profile in SL transfected with negative control (scrambled), miR 21 mimic, miR 21 inhibitor and cultured for 67h. (A) SL from dogs with CanL and (B) SL from control non-infected dogs. Data represent the mean values of Th1/Th2 + standard error of the mean. Asterisks represent significance (p<0.05) by Friedman Test with multiple comparison.
Fig 4Parasite load.
Parasite load in cultures of SL naturally infected by L. infantum and transfected with negative control (scrambled), miR 21 mimic, miR 21 inhibitor for 67h. Data represent mean + standard error of the mean. Asterisks represent significance (p<0.05) by Friedman Test with multiple comparison.